Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 mutant Nutlin-3a neuroblastoma resistant detail...
TP53 mutant MI-63 neuroblastoma resistant detail...
ALK R1275Q Crizotinib + Cyclophosphamide + Topotecan neuroblastoma sensitive detail...
ALK F1174L TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma sensitive detail...
ALK F1245C TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma sensitive detail...
ALK act mut TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma predicted - sensitive detail...
ALK wild-type TP53 H168R Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
ALK wild-type MDM2 amp TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
ALK mut TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma sensitive detail...
ALK wild-type TP53 C176F Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
ALK wild-type TP53 P177T Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
ALK wild-type TP53 mut Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
ALK amp TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma sensitive detail...
ALK wild-type TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
TP53 wild-type GSK2830371 neuroblastoma predicted - sensitive detail...
TP53 mutant GSK2830371 neuroblastoma resistant detail...
TP53 wild-type Carboplatin + GSK2830371 neuroblastoma predicted - sensitive detail...
TP53 wild-type Doxorubicin + GSK2830371 neuroblastoma predicted - sensitive detail...
ALK F1174V Brigatinib neuroblastoma sensitive detail...
ALK F1174L Crizotinib neuroblastoma conflicting detail...
ALK F1245C Crizotinib neuroblastoma resistant detail...
ALK R1275Q Crizotinib neuroblastoma conflicting detail...
EML4 - ALK Crizotinib neuroblastoma resistant detail...
ALK amp Crizotinib neuroblastoma no benefit detail...
ALK F1174L Lorlatinib neuroblastoma predicted - sensitive detail...
ALK F1245C Lorlatinib neuroblastoma sensitive detail...
ALK R1275Q Lorlatinib neuroblastoma sensitive detail...
EML4 - ALK Lorlatinib neuroblastoma sensitive detail...
ALK amp Lorlatinib neuroblastoma sensitive detail...
ALK wild-type Lorlatinib neuroblastoma resistant detail...
MDM2 over exp TP53 wild-type MX69 neuroblastoma sensitive detail...
ALK positive Entrectinib neuroblastoma sensitive detail...
ALK F1245V Entrectinib neuroblastoma predicted - sensitive detail...
ALK D1091N Alectinib neuroblastoma predicted - sensitive detail...
ALK D1091N Alectinib + Doxorubicin neuroblastoma predicted - sensitive detail...
ALK D1091N AZD3463 neuroblastoma sensitive detail...
ALK D1091N AZD3463 + Doxorubicin neuroblastoma sensitive detail...
ALK F1174L ALK L1198P Crizotinib neuroblastoma resistant detail...
ALK G1123S ALK F1174L TAE684 neuroblastoma resistant detail...
ALK F1174L ALK L1198P TAE684 neuroblastoma resistant detail...
ALK G1123D ALK F1174L TAE684 neuroblastoma resistant detail...
ALK R1275Q CEP-28122 neuroblastoma sensitive detail...
ALK F1174L CEP-28122 neuroblastoma sensitive detail...
ALK amp CEP-28122 neuroblastoma sensitive detail...
ALK wild-type CEP-28122 neuroblastoma resistant detail...
ALK F1174L AZD3463 neuroblastoma sensitive detail...
NRAS mutant Alpelisib + Binimetinib neuroblastoma sensitive detail...
ALK F1174V ALK amp Ceritinib neuroblastoma sensitive detail...
ALK F1174L ALK amp Ceritinib neuroblastoma sensitive detail...
ALK R1275Q Ceritinib neuroblastoma sensitive detail...
ALK F1174V ALK amp Crizotinib neuroblastoma sensitive detail...
ALK F1174L ALK amp Crizotinib neuroblastoma sensitive detail...
ATM P960H Olaparib neuroblastoma sensitive detail...
ATM S1455R Olaparib neuroblastoma sensitive detail...
ATM V1841I Olaparib neuroblastoma sensitive detail...
ATM L1874F Olaparib neuroblastoma sensitive detail...
ATM H2038Y Olaparib neuroblastoma sensitive detail...
ATM K2749I Olaparib neuroblastoma sensitive detail...
ATM A59S Olaparib neuroblastoma sensitive detail...
ATM P604S Olaparib neuroblastoma sensitive detail...
ATM V519I Olaparib neuroblastoma sensitive detail...
ATM S824F Olaparib neuroblastoma sensitive detail...
ATM L1956H Olaparib neuroblastoma no benefit detail...
ATM R2691C Olaparib neuroblastoma no benefit detail...
CD274 positive Pembrolizumab neuroblastoma predicted - sensitive detail...
ALK R1275Q Belizatinib neuroblastoma no benefit detail...
NRAS Q61K SHP099 neuroblastoma predicted - resistant detail...
NRAS Q61K Trametinib neuroblastoma predicted - sensitive detail...
NRAS Q61K Ulixertinib neuroblastoma predicted - sensitive detail...
NRAS Q61K SHP099 + Trametinib neuroblastoma sensitive detail...
NRAS Q61K SHP099 + Ulixertinib neuroblastoma sensitive detail...
NRAS Q61K SHP099 + Vemurafenib neuroblastoma sensitive detail...
NRAS Q61K Vemurafenib neuroblastoma no benefit detail...
NRAS Q61K Rigosertib neuroblastoma not predictive detail...
ALK F1174V Crizotinib neuroblastoma predicted - sensitive detail...
ALK F1174L ALK R1275Q Crizotinib neuroblastoma predicted - sensitive detail...
ALK F1174L Crizotinib + Cyclophosphamide + Topotecan neuroblastoma conflicting detail...
ALK R1275L Crizotinib neuroblastoma predicted - sensitive detail...
NRAS Q61K ERAS-007 neuroblastoma sensitive detail...
ALK L1196M Ceritinib neuroblastoma predicted - sensitive detail...
ALK positive Ceritinib neuroblastoma predicted - sensitive detail...
ALK R1275Q Vandetanib neuroblastoma sensitive detail...
ALK F1174L Vandetanib neuroblastoma sensitive detail...
ALK F1174L Entrectinib neuroblastoma predicted - sensitive detail...
FGFR1 N546K AZD4547 + Pictilisib neuroblastoma sensitive detail...
ALK F1174L TQ-B3139 neuroblastoma sensitive detail...
ALK F1174L Repotrectinib neuroblastoma sensitive detail...
ALK F1174V ALK amp Repotrectinib neuroblastoma sensitive detail...
ALK amp Repotrectinib neuroblastoma predicted - sensitive detail...
ALK amp Ensartinib neuroblastoma predicted - sensitive detail...
ALK R1275Q Ensartinib neuroblastoma predicted - sensitive detail...
ALK R1275Q Repotrectinib neuroblastoma predicted - sensitive detail...
ALK F1174V Repotrectinib neuroblastoma predicted - resistant detail...
ALK F1174V Irinotecan + Repotrectinib + Temozolomide neuroblastoma predicted - sensitive detail...
NRAS Q61K BI-1347 + Trametinib neuroblastoma sensitive detail...
NRAS Q61K BI-1347 + Selumetinib neuroblastoma sensitive detail...
ALK amp TP53 wild-type Idasanutlin + Lorlatinib neuroblastoma sensitive detail...
ALK F1174C TP53 wild-type Idasanutlin + Lorlatinib neuroblastoma resistant detail...
ALK F1174L TP53 wild-type Idasanutlin + TAE684 neuroblastoma sensitive detail...
ALK R1275Q TP53 wild-type Idasanutlin + TAE684 neuroblastoma sensitive detail...
ALK amp MDM2 amp TP53 wild-type Idasanutlin + TAE684 neuroblastoma sensitive detail...
ALK F1174V ALK amp TP53 wild-type Idasanutlin + TAE684 neuroblastoma sensitive detail...
ALK F1174L TP53 wild-type Alectinib + Idasanutlin neuroblastoma sensitive detail...
ALK R1275Q TP53 wild-type Alectinib + Idasanutlin neuroblastoma sensitive detail...
ALK amp TP53 wild-type Alectinib + Idasanutlin neuroblastoma sensitive detail...
ALK F1174V ALK amp TP53 wild-type Alectinib + Idasanutlin neuroblastoma sensitive detail...
ALK F1174L Cyclophosphamide + Doxorubicin + Lorlatinib + Vincristine Sulfate neuroblastoma sensitive detail...
ALK amp Cyclophosphamide + Doxorubicin + Lorlatinib + Vincristine Sulfate neuroblastoma no benefit detail...
ALK F1174C Cyclophosphamide + Doxorubicin + Lorlatinib + Vincristine Sulfate neuroblastoma predicted - sensitive detail...
NRAS act mut Navitoclax + Trametinib neuroblastoma predicted - sensitive detail...
ALK act mut Navitoclax + Trametinib neuroblastoma predicted - sensitive detail...
ALK act mut Trametinib + Venetoclax neuroblastoma predicted - sensitive detail...
NRAS act mut Trametinib + Venetoclax neuroblastoma predicted - sensitive detail...
NRAS act mut S63845 + Trametinib neuroblastoma predicted - sensitive detail...
ALK act mut S63845 + Trametinib neuroblastoma predicted - sensitive detail...
ALK F1174L NRAS Q61K Ceritinib neuroblastoma resistant detail...
ALK F1174L NRAS Q61K Lorlatinib neuroblastoma resistant detail...
ALK F1174L FGFR1 N546K Lorlatinib neuroblastoma predicted - resistant detail...
ALK F1245V Lorlatinib neuroblastoma predicted - sensitive detail...
ALK I1171T ALK R1192P ALK L1196M ALK F1245V Lorlatinib neuroblastoma predicted - resistant detail...
ALK G1202R ALK R1275Q BRAF V600E Lorlatinib neuroblastoma predicted - resistant detail...
ALK F1174C Lorlatinib neuroblastoma predicted - sensitive detail...
ALK F1174L PIK3CA H1047R Lorlatinib neuroblastoma predicted - resistant detail...
ALK F1174L ALK G1202R ALK D1203N ALK amp Lorlatinib neuroblastoma predicted - resistant detail...
ALK F1174L ALK L1196M Lorlatinib neuroblastoma resistant detail...
ALK F1174L ALK G1202R Lorlatinib neuroblastoma resistant detail...
ALK G1202R ALK R1275Q Lorlatinib neuroblastoma resistant detail...
ALK L1196M ALK R1275Q Lorlatinib neuroblastoma resistant detail...
ALK F1245Y HRAS G13R Lorlatinib neuroblastoma predicted - resistant detail...
ALK D1276_R1279delinsE Crizotinib neuroblastoma predicted - sensitive detail...
ALK G1202R ALK D1276_R1279delinsE Crizotinib neuroblastoma predicted - resistant detail...
ALK G1202R ALK D1276_R1279delinsE Lorlatinib neuroblastoma predicted - sensitive detail...
ALK R1275Q Ceritinib + Ribociclib neuroblastoma sensitive detail...
ALK F1174L Ceritinib + Ribociclib neuroblastoma sensitive detail...
ALK F1245C Ceritinib + Ribociclib neuroblastoma sensitive detail...
ALK del exon2 ALK del exon3 ALK amp Ceritinib + Ribociclib neuroblastoma sensitive detail...
ALK amp TP53 wild-type Ceritinib + CGM097 neuroblastoma sensitive detail...
ALK F1174L TP53 wild-type Ceritinib + CGM097 neuroblastoma sensitive detail...
ALK R1275Q TP53 wild-type Ceritinib + CGM097 neuroblastoma sensitive detail...
NRAS Q61K 4SC-205 + Selumetinib neuroblastoma sensitive detail...
ALK F1174L 4SC-205 + Ceritinib neuroblastoma sensitive detail...
ALK F1174L 4SC-205 + Lorlatinib neuroblastoma sensitive detail...
ALK F1174L CCC-003 neuroblastoma sensitive detail...
ALK F1245Y Lorlatinib neuroblastoma predicted - sensitive detail...
ALK act mut Lorlatinib neuroblastoma sensitive detail...
ALK act mut Cyclophosphamide + Lorlatinib + Topotecan neuroblastoma sensitive detail...
ALK F1245I Lorlatinib neuroblastoma sensitive detail...
ALK F1245I Ceritinib neuroblastoma sensitive detail...
ALK F1245I Crizotinib neuroblastoma sensitive detail...
ALK F1245I Alectinib neuroblastoma sensitive detail...
ALK F1174V Lorlatinib neuroblastoma sensitive detail...
ALK act mut NUV-655 neuroblastoma predicted - sensitive detail...
ALK amp NUV-655 neuroblastoma predicted - sensitive detail...
ALK F1174L TNO155 neuroblastoma sensitive detail...
ALK R1275Q TNO155 neuroblastoma sensitive detail...
ALK F1174L Ceritinib neuroblastoma sensitive detail...
ALK D1091N Ceritinib neuroblastoma sensitive detail...
ALK D1091N Crizotinib neuroblastoma sensitive detail...
ALK D1091N Lorlatinib neuroblastoma predicted - sensitive detail...
ALK F1174L Ceritinib + TNO155 neuroblastoma sensitive detail...
ALK R1275Q Ceritinib + TNO155 neuroblastoma sensitive detail...
ALK F1174L Lorlatinib + TNO155 neuroblastoma sensitive detail...
ALK R1275Q Lorlatinib + TNO155 neuroblastoma sensitive detail...
ALK F1174L Crizotinib + TNO155 neuroblastoma sensitive detail...
ALK R1275Q Crizotinib + TNO155 neuroblastoma sensitive detail...
ALK F1174L Crizotinib + SHP099 neuroblastoma sensitive detail...
ALK R1275Q Crizotinib + SHP099 neuroblastoma sensitive detail...
ALK F1174L Ceritinib + SHP099 neuroblastoma sensitive detail...
ALK R1275Q Ceritinib + SHP099 neuroblastoma sensitive detail...
ALK F1174L Lorlatinib + SHP099 neuroblastoma sensitive detail...
ALK R1275Q Lorlatinib + SHP099 neuroblastoma sensitive detail...
ALK F1174L SHP099 neuroblastoma sensitive detail...
ALK R1275Q SHP099 neuroblastoma sensitive detail...
ALK del exon4-11 Lorlatinib neuroblastoma sensitive detail...
ALK del exon4-11 Entrectinib neuroblastoma sensitive detail...
ALK F1174V Entrectinib neuroblastoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT00089245 Phase I Omburtamab I-131 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Terminated USA 0
NCT00601003 Phase II Cyclophosphamide + Nifurtimox + Topotecan Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Completed USA 0
NCT00602667 Phase I Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Cyclophosphamide + Etoposide + Topotecan Cyclophosphamide + Erlotinib + Topotecan Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting USA | AUS 0
NCT00885326 Phase I Bevacizumab + Cyclophosphamide + Zoledronic acid N2007-02:Bevacizumab,Cyclophosphamide,and Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Completed USA | CAN 0
NCT00911560 Phase Ib/II Beta-glucan GD2-GD3 vaccine Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral beta-glucan for High-Risk Neuroblastoma Active, not recruiting USA 0
NCT00939770 Phase Ib/II Crizotinib Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed USA | CAN 0
NCT01175356 Phase I Busulfan + Melphalan Cyclophosphamide + Topotecan 131I-MIBG Cyclophosphamide + Doxorubicin + Vincristine Sulfate Cisplatin + Etoposide Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Active, not recruiting USA 0
NCT01241162 Phase I Decitabine Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed USA 0
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed USA 0
NCT01492673 Phase II Bevacizumab + Cyclophosphamide + Topotecan Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Completed USA | CAN 0
NCT01518413 Phase I Irinotecan + Sorafenib Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed USA 0
NCT01526603 Phase I Melphalan Etoposide Filgrastim Tretinoin Carboplatin High Dose Chemotherapy and Autologous Transplant for Neuroblastoma Completed USA 0
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA | GBR | FRA | ESP | AUS 2
NCT01601535 Phase Ib/II Alisertib + Irinotecan + Temozolomide Study of MLN8237 in Combination With Irinotecan and Temozolomide Completed USA | CAN 0
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Completed USA 0
NCT01704716 Phase III Busulfan + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Filgrastim Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Dinutuximab beta Aldesleukin + Dinutuximab beta Carboplatin + Etoposide + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) Recruiting ITA | GBR | FRA | ESP | BEL | AUT | AUS 13
NCT01747876 Phase I Ribociclib Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma Terminated USA | GBR | FRA | DEU | AUS 0
NCT01757626 Phase Ib/II Naxitamab + Sargramostim Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma Active, not recruiting USA 0
NCT01767194 Phase II Dinutuximab Temsirolimus Irinotecan + Temozolomide Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Completed USA | CAN | AUS 2
NCT01822652 Phase I Cyclophosphamide Fludarabine Pembrolizumab 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN Active, not recruiting USA 0
NCT01838187 Expanded access Vorinostat Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma No longer available USA 0
NCT01857934 Phase II Doxorubicin Sargramostim Aldesleukin Vincristine Sulfate Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan Therapy for Children With Advanced Stage Neuroblastoma Active, not recruiting USA 0
NCT01956669 Phase II Pazopanib Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Completed USA | FRA | ESP | CAN 3
NCT02013336 Phase I Cyclophosphamide + Liposomal irinotecan Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors Unknown status USA 0
NCT02030964 Phase I Cyclophosphamide + Topotecan Celecoxib N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Active, not recruiting USA | CAN | AUS 0
NCT02035137 Phase II 131I-MIBG 131I-MIBG + Irinotecan + Vincristine Sulfate 131I-MIBG + Vorinostat 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat (N2011-01) Completed USA | CAN 0
NCT02075177 Phase I Ketoconazole Fenretinide Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma No longer available USA 0
NCT02095132 Phase Ib/II Adavosertib + Irinotecan Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Completed USA | CAN 0
NCT02100891 Phase II Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Completed USA 0
NCT02124772 Phase I Trametinib Dabrafenib + Trametinib Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Completed USA | GBR | FRA | CAN | AUS 0
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed USA 0
NCT02139397 Phase Ib/II Eflornithine Bortezomib Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma Active, not recruiting USA 0
NCT02163356 Phase I Vincristine Sulfate Fenretinide Ketoconazole Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma Terminated USA 0
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-aATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Unknown status USA 0
NCT02298348 Phase I Cyclophosphamide + Sorafenib + Topotecan Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma Active, not recruiting USA | CAN 0
NCT02303028 Phase Ib/II Pazopanib + Topotecan Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours Completed CAN 0
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Completed USA | CAN 0
NCT02308527 Phase II Bevacizumab + Irinotecan + Temozolomide Temozolomide + Topotecan Bevacizumab + Temozolomide Bevacizumab + Temozolomide + Topotecan Dinutuximab beta + Temozolomide Temozolomide Dinutuximab beta + Temozolomide + Topotecan Irinotecan + Temozolomide Cyclophosphamide + Dinutuximab beta + Topotecan Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children (BEACON) Active, not recruiting ITA | GBR | FRA | ESP | BEL | AUT 4
NCT02311621 Phase I CE7R CAR T cells Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 Active, not recruiting USA 0
NCT02337309 Phase I SF1126 SF1126 for Patients With Relapsed or Refractory Neuroblastoma Terminated USA 0
NCT02372006 Phase Ib/II Afatinib Trial of Afatinib in Pediatric Tumours Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 3
NCT02378428 Phase II 131I-MIBG MIBG Therapy for Patients With MIBG Avid Tumors Active, not recruiting USA 0
NCT02508038 Phase I Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa Recruiting USA 0
NCT02559778 Phase I Bortezomib Crizotinib Lapatinib Vorinostat Eflornithine Sorafenib Dasatinib Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN) Recruiting USA | CAN 0
NCT02573896 Phase I Dinutuximab + Lenalidomide Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells Active, not recruiting USA 0
NCT02574728 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting USA 0
NCT02639546 Phase Ib/II Cobimetinib Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) Completed USA | ITA | GBR | FRA | ESP | DEU 1
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Completed USA 0
NCT02650401 Phase I Entrectinib Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 4
NCT02650648 Phase I Aldesleukin + Cyclophosphamide + Naxitamab Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma Active, not recruiting USA 0
NCT02748135 Phase Ib/II TB-403 A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma Completed USA 0
NCT02780128 Phase I Siremadlin Ceritinib + Ribociclib Trametinib Next Generation Personalized Neuroblastoma Therapy Terminated USA 0
NCT02789228 Phase I MultiTAA-specific T cells Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) Active, not recruiting USA 0
NCT02909777 Phase I CUDC-907 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Active, not recruiting USA 0
NCT02914405 Phase I Dinutuximab beta + Nivolumab Nivolumab Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma (MiniVan) Recruiting USA | GBR 0
NCT02982941 Phase I MGA271 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Completed USA 0
NCT03033303 Phase II Isotretinoin + Naxitamab + Sargramostim A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma Active, not recruiting USA 0
NCT03107988 Phase I Cyclophosphamide + Lorlatinib + Topotecan Lorlatinib NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Active, not recruiting USA | GBR | FRA | CAN 0
NCT03126916 Phase III Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Sulfate Cisplatin Cyclophosphamide Thiotepa Dexrazoxane Lorlatinib Carboplatin Aldesleukin Topotecan Dinutuximab Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Active, not recruiting USA | CAN 1
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA | CAN | AUS 1
NCT03189706 Phase I Irinotecan + Naxitamab + Sargramostim + Temozolomide Study of Chemoimmunotherapy for High-Risk Neuroblastoma Active, not recruiting USA 0
NCT03209869 Phase I hu14.18-IL2 Treatment of Relapsed or Refractory Neuroblastoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 Withdrawn USA 0
NCT03210714 Phase II Erdafitinib Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213652 Phase II Ensartinib Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Recruiting USA | AUS 1
NCT03213678 Phase II LY3023414 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213691 Phase II Selumetinib Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03233204 Phase II Olaparib Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03275402 Phase II Omburtamab I-131 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases Terminated USA | ESP 2
NCT03332667 Phase I 131I-MIBG + Dinutuximab + Sargramostim + Vorinostat 131I-MIBG + Dinutuximab + Sargramostim MIBG With Dinutuximab +/- Vorinostat Active, not recruiting USA 0
NCT03363373 Phase III Naxitamab + Sargramostim Naxitamab for Neuroblastoma With Osteomedullary Disease Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 2
NCT03373097 Phase Ib/II GD2-CART01 Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors Recruiting ITA 0
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Terminated USA 0
NCT03478462 Phase I CLR 131 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Active, not recruiting USA | CAN | AUS 0
NCT03526250 Phase II Palbociclib Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03561259 Phase II 131I-MIBG + Vorinostat 131I-MIBG A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUM) Recruiting USA 0
NCT03581240 Expanded access Eflornithine An Intermediate Expanded Use Trial of DFMO Available USA 0
NCT03585465 Phase Ib/II Capecitabine + Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Cyclophosphamide + Vinblastine Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Nivolumab Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors Suspended FRA | BEL 0
NCT03635632 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Active, not recruiting USA 0
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03709680 Phase I Irinotecan + Palbociclib + Temozolomide Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 13
NCT03721068 Phase I iC9.GD2.CAR.IL-15 T-cells Cyclophosphamide + Fludarabine Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma Recruiting USA 0
NCT03786783 Phase II Isotretinoin Cyclophosphamide + Thiotepa Cisplatin + Dinutuximab + Etoposide + Sargramostim Cyclophosphamide + Dinutuximab + Doxorubicin + Sargramostim + Vincristine Sulfate Dexrazoxane Cyclophosphamide + Topotecan Dinutuximab + Isotretinoin + Sargramostim Carboplatin + Etoposide + Melphalan Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Active, not recruiting USA | AUS 1
NCT03794349 Phase II Dinutuximab + Irinotecan + Sargramostim + Temozolomide Dinutuximab + Eflornithine + Irinotecan + Sargramostim + Temozolomide Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Active, not recruiting USA | CAN | AUS 2
NCT03838042 Phase Ib/II Entinostat + Nivolumab INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) Recruiting FRA | DEU | AUT | AUS 3
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Terminated USA 0
NCT04029688 Phase Ib/II Idasanutlin + Venetoclax Cyclophosphamide + Idasanutlin + Topotecan Cytarabine + Fludarabine + Idasanutlin Cytarabine + Hydrocortisone + Methotrexate Cytarabine Methotrexate Idasanutlin Cyclophosphamide + Idasanutlin A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Recruiting USA | GBR | FRA | ESP | CAN 1
NCT04106219 Phase I LY3295668 Cyclophosphamide + LY3295668 + Topotecan A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 1
NCT04211675 Phase Ib/II Dinutuximab + Irinotecan + Sargramostim + Temozolomide NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (STING) Recruiting USA 0
NCT04221035 Phase III Busulfan + Melphalan + Thiotepa Dinutuximab beta Cisplatin + Etoposide + Vindesine Dacarbazine + Doxorubicin + Ifosfamide + Vincristine Sulfate Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate Busulfan + Melphalan High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2) Recruiting ITA | GBR | FRA | ESP | BEL | AUS 10
NCT04239040 Phase I GVAX + Ipilimumab + Nivolumab GVAX Plus Checkpoint Blockade in Neuroblastoma Recruiting USA 0
NCT04284774 Phase II Tipifarnib Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Active, not recruiting USA 1
NCT04301843 Phase II Eflornithine + Etoposide Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma Recruiting USA | CAN 0
NCT04385277 Phase II Dinutuximab + Irinotecan + Isotretinoin + Sargramostim + Temozolomide Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) Active, not recruiting USA | CAN | AUS 1
NCT04500548 Phase I Nivolumab Ipilimumab + Nivolumab Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Withdrawn USA | CAN 0
NCT04501757 Expanded access Naxitamab + Sargramostim Naxitamab and GM-CSF in People With Neuroblastoma No longer available USA 0
NCT04544995 Phase I Dostarlimab-gxly + Niraparib Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors Suspended GBR | FRA | ESP | DEU 2
NCT04560166 Phase II Irinotecan + Naxitamab + Sargramostim + Temozolomide Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma Terminated 2
NCT04730349 Phase Ib/II Nivolumab + NKTR-214 A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020) Terminated USA | ITA | FRA | ESP | DEU | AUS 0
NCT04751383 Phase I Dinutuximab + Hu5F9-G4 Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma Suspended USA | CAN 0
NCT04897880 Phase II Panobinostat A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH) Terminated USA | AUS 1
NCT05004116 Phase Ib/II Irinotecan + Repotrectinib + Temozolomide A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer Recruiting USA 0
NCT05064306 Expanded access Omburtamab I-131 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults Available USA 0
NCT05135975 Phase II Cabozantinib A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Recruiting USA 0
NCT05421897 FDA approved Cyclophosphamide + Dinutuximab + Irinotecan + Sargramostim + Temozolomide + Topotecan Rapid Administration Pilot for Infusing Dinutuximab (RAPID) Recruiting USA 0
NCT05429502 Phase Ib/II Ribociclib + Temozolomide + Topotecan Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU | AUS 1
NCT05489887 Phase II Ceritinib + Naxitamab Naxitamab Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma Recruiting USA | CAN 0
NCT05650749 Phase I GPC2 CAR-T cells GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (GPC2) Recruiting USA 0